Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing gene-targeted therapies for degenerative genetic diseases, is set to present the latest developments on its eye drop candidate DT-168 for Fuchs endothelial corneal dystrophy on Friday, May 2, 2025.
DT-168 is a GeneTAC small-molecule therapy formulated as an eye drop for the treatment of Fuchs endothelial corneal dystrophy or FECD, a progressive eye disease with no approved disease-modifying therapies.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com